rolipram has been researched along with Respiratory Distress Syndrome in 7 studies
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a rat model of lipopolysaccharide (LPS)-induced pulmonary inflammation, the antiinflammatory activity of SB 207499 was evaluated and compared to that of the prototypic type-4 phosphodiesterase (PDE4) inhibitor, rolipram." | 3.71 | Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. ( Chapman, R; Fine, J; Jones, H; Kreutner, W; Kung, TT; Minnicozzi, M; Spond, J, 2001) |
| "Pretreatment with rolipram also attenuated increases in serum tumor necrosis factor alpha (TNFalpha) levels induced by LPS and zymosan treatment, measured after 2." | 1.30 | Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. ( Hellewell, PG; Miotla, JM; Teixeira, MM, 1998) |
| "Rolipram pretreatment was protective against LPS-induced mortality and also resulted in reduced plasma TNF alpha concentrations." | 1.29 | Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. ( Esser, KM; Turner, CR; Wheeldon, EB, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Lima, FM | 1 |
| Moreira, LM | 1 |
| Villaverde, AB | 1 |
| Albertini, R | 1 |
| Castro-Faria-Neto, HC | 1 |
| Aimbire, F | 1 |
| Hamamoto, M | 1 |
| Suga, M | 1 |
| Nakatani, T | 1 |
| Takahashi, Y | 1 |
| Sato, Y | 1 |
| Inamori, S | 1 |
| Yagihara, T | 1 |
| Kitamura, S | 1 |
| de Visser, YP | 1 |
| Walther, FJ | 1 |
| Laghmani, EH | 1 |
| van Wijngaarden, S | 1 |
| Nieuwland, K | 1 |
| Wagenaar, GT | 1 |
| Howell, RE | 1 |
| Jenkins, LP | 1 |
| Howell, DE | 1 |
| Turner, CR | 1 |
| Esser, KM | 1 |
| Wheeldon, EB | 1 |
| Miotla, JM | 1 |
| Teixeira, MM | 1 |
| Hellewell, PG | 1 |
| Spond, J | 1 |
| Chapman, R | 1 |
| Fine, J | 1 |
| Jones, H | 1 |
| Kreutner, W | 1 |
| Kung, TT | 1 |
| Minnicozzi, M | 1 |
7 other studies available for rolipram and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.
Topics: Animals; Base Sequence; Cyclic AMP; Disease Models, Animal; DNA Primers; Lipopolysaccharides; Low-Le | 2011 |
Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiopulmonary Bypass; CD11b Antigen; Cyclic Nucleoti | 2004 |
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
Topics: Animals; Animals, Newborn; Benzamides; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Ex | 2008 |
Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Topics: Aerosols; Aminophylline; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Dexamethas | 1995 |
Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; | 1993 |
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillary Permeability; Cyclic Nucleotide Phosphodiest | 1998 |
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Topics: Adrenalectomy; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Humans; Inflammation; I | 2001 |